Anti-Human CD2 [Clone G11] — Purified in vivo PLATINUM™ Functional Grade

Clone G11 can refer to several distinct entities, but in the context of in vivo mouse studies, the most documented example is the EGFP-mouse embryonic stem cell (mESC) clone G11, which is used for cell transplantation and lineage tracing.

Main Use in In Vivo Mouse Studies:

• Clone G11 (EGFP-mESC): This is a mouse embryonic stem cell line derived from transgenic mice that express enhanced green fluorescent protein (EGFP) under the control of the ß-actin promoter. In in vivo studies, clone G11 cells are injected into mouse embryos or adult tissues, where they can integrate, differentiate, and contribute to various tissues. Their EGFP label allows researchers to track these cells and their progeny over time.
  • Applications include:
    • Generating chimeric mice to study developmental potential.
    • Cell transplantation experiments, for example, by differentiating G11 cells into neurons and injecting them into mouse brains. EGFP fluorescence enables long-term tracking of transplanted cells after integration, such as in neural tissue for over 12 weeks post-transplantation.
    • Tracing cell fate and tissue distribution of ESC-derived progeny in regenerative medicine or allotransplantation models.

Additional Details:

• Advantages: G11 cells avoid pitfalls of artificial labeling or gene transfer, offering a reliable model for in vivo studies due to endogenous fluorescence.
• Experimental Controls: G11 cells have been validated for pluripotency, karyotype stability, and differentiation ability both in vitro and in vivo.

If you are referring to a different G11 clone (e.g., antibody, peptide, or other cell types), please specify, as clone designations are commonly reused. For example:

• ScFv G11 antibody: In other contexts, "G11" refers to a single-chain antibody used in mouse models for tumor targeting, where genetic fusion to iRGD peptide enhances tumor penetration.
• Anti-mouse PD-1 clone 4C11: Sometimes compared to other G-series clones, used for immunotherapy studies, but not directly related to clone G11.

Summary Table: Use of Clone G11 in Mouse In Vivo Studies

Key Point: If your study uses EGFP-mESC clone G11, its main role is as a traceable pluripotent stem cell in cell replacement, tissue integration, and fate mapping experiments in mice. If referring to another G11 clone (such as an antibody or peptide derivative), clarify for a more targeted summary.

Other commonly used antibodies and proteins with G11 in the literature—especially for tumor targeting—include the antibody fragment scFv(G11) in different engineered formats and fusion proteins such as scFv(G11)-interleukin-2 (IL2) and fusion with the iRGD peptide.

Key examples:

• ScFv(G11) SIP Format: G11 has been fused to different immunoglobulin domains for enhanced bivalent binding, such as the SIP (small immunoprotein) format using the human ?CH4 domain of secretory IgE, facilitating homodimer formation.
• ScFv(G11)-IL2: Genetic fusion with human interleukin-2 creates a cytokine–antibody fusion used to study and enhance immune targeting of tumors. This format is largely monomeric under physiological conditions, distinct from EDB-targeting scFv(L19)-IL2, which can form non-covalent homodimers.
• ScFv(G11)-iRGD Peptide Fusion: Fusion of the G11 single-chain variable fragment with the tumor-penetrating peptide iRGD has been shown to improve homing, extravasation, and penetration in tumor models.
• Comparison/Alternatives: Another antibody often referenced together with G11 is scFv(L19), targeting a different domain (extra-domain B) of tenascin-C; these are frequently compared for tumor targeting in similar therapeutic approaches.

Besides engineered antibody formats, protein A, protein G, and protein L are frequently used in purification, detection, and assay development for antibodies including G11:

• Protein A and Protein G: Used for purification and detection of IgG antibodies and their fragments via Fc binding.
• Protein L: Used for binding and detection of antibody fragments and light chain variants, including scFvs like G11.

In summary, G11 is commonly used in formats engineered for targeted therapy (e.g., SIP, IL2 fusion, iRGD fusion), and paired with proteins for detection and purification (Protein A, G, L); it is also compared with or used alongside other tenascin-C targeting antibodies such as L19.

Key findings from scientific literature show that antibodies or protein clones designated G11 have been developed and studied in several distinct contexts, with key results highlighted below.

1. Anti-feline PD-L1 Antibody Clone G11-6 (Cancer/Immunotherapy):

• Clone G11-6 binds to endogenous feline PD-L1 (programmed death-ligand 1).
• Its binding was confirmed on three out of five feline mammary adenocarcinoma cell lines, a T-cell lymphoma line, and a B-cell lymphoma line, but not on macrophage or fibroblast cell lines.
• This suggests G11-6 is a specific and effective antibody for detecting PD-L1 in certain feline cancer types and may support immunotherapeutic research in cats.

2. Human scFv(G11) to Tenascin-C Domain C (Tumor Targeting):

• scFv(G11) is a human single-chain antibody fragment that selectively targets domain C of tenascin-C, an extracellular matrix protein upregulated in tumors.
• This clone displayed the slowest kinetic dissociation (i.e., high binding stability) among a candidate panel, suggesting its potential use in targeted cancer therapy or imaging.

3. Clone G11 in pH-dependent Antibody Selection (Chemokine Targeting):

• G11 was one of several antibodies isolated for their pH-dependent binding to the mouse chemokine CXCL10.
• Reformatted as a human IgG, clone G11 demonstrated the ability to bind CXCL10 at neutral pH and showed reduced binding at acidic pH, characteristic of endosomal environments.
• This property may enable selective neutralization of CXCL10 in specific tissue compartments, with potential for therapeutic applications where pH-responsiveness is an advantage.

Summary Table: Key G11-related Findings

Note: The "G11" designation appears independently in multiple research settings and refers to different antibodies or clones, depending on the study. Therefore, precise context is essential when interpreting "clone G11" findings. No direct connection exists between these clones other than the coincidence of their lab-assigned names in separate research lines.

There is insufficient information in the available search results to provide specific details about the dosing regimens of clone G11 across different mouse models. The sources reviewed cover general antibody dosing strategies, recommended doses for other common clones (such as 9H10, GK1.5, and 2.43), and background on mouse models for immunotherapy and glioblastoma, but do not mention clone G11 or its dosing protocols.

• In general, antibody dosing regimens in mouse models vary by clone, target antigen, experimental goal, administration route (commonly intraperitoneal), and schedule (such as every 2–3 days or 2–3 times per week). The typical dose range for many in vivo antibodies is 100–250??g per mouse, but guidance for clone G11 specifically is not included in these references.
• If clone G11 is similar to regularly used antibodies for immunotherapy or immune cell depletion, the recommended approach is to review peer-reviewed literature for that clone or consult in vivo antibody dosing guides.
• Dosing can be affected by mouse model type (xenograft, syngeneic, genetically engineered), disease context (e.g., cancer subtype, immune status), and experimental endpoints.

In summary, to accurately determine how dosing regimens of clone G11 vary, consult the primary literature on G11 or specific datasheets. The general principles from antibody dosing guides—considering dose, route, schedule, and mouse model specifics—apply, but explicit parameters for G11 must be sourced directly from dedicated studies or antibody manufacturers.